

Korlym® (mifepristone) - First-time generic

- On January 19, 2024, <u>Teva launched</u> an <u>AB-rated</u> generic version of Corcept Therapeutics' <u>Korlym (mifepristone)</u> 300 mg tablets.
- Korlym is approved to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
- Korlym carries a boxed warning for termination of pregnancy.
- Mifepristone is also available generically as a <u>200 mg tablet</u> indicated in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.